|
| 37349954 | A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm. | | 2023 |
| 36345655 | When the personal becomes political: The impact of the Dobbs decision on women with cancer. | Cancer | 2023 |
| 37568775 | The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer. | Cancers (Basel) | 2023 |
| 37149421 | Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics. | | 2023 |
| 36897465 | Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. | | 2023 |
| 37207300 | Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. | J Clin Oncol | 2023 |
| 37330052 | Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. | Ann Oncol | 2023 |
| 37170847 | Margetuximab in HER2-positive metastatic breast cancer. | | 2023 |
| 37419745 | Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years? | | 2023 |
| 35084624 | Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. | Breast Cancer Research and Treatment | 2022 |
| 35396812 | A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). | Cancer Med | 2022 |
| 36136177 | Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases. | Current Treatment Options in Oncology | 2022 |
| 36057835 | Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. | Breast Disease | 2022 |
| 35599460 | Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report. | Breast Disease | 2022 |
| 34965945 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. | Clin Cancer Res | 2022 |
| 35201844 | Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. | Journal of Clinical Oncology | 2022 |
| 34583980 | Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer. | Molecular Cancer Therapeutics | 2021 |
| 34047359 | Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all? | Cancer | 2021 |
| 33727258 | Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. | Clin Cancer Res | 2021 |
| 34030860 | Introduction to Special Issue. | Clinical Breast Cancer | 2021 |
| 32997608 | Benchmarks for Academic Oncology Faculty. | JCO Oncol Pract | 2021 |
| 34629314 | Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies. | Clinical Breast Cancer | 2021 |
| 34794122 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. | J Natl Compr Canc Netw | 2021 |
| 34516829 | Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. | Science Translational Medicine | 2021 |
| 34769309 | PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. | International Journal of Molecular Sciences | 2021 |
| 34712959 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. | Nat Cancer | 2021 |
| 32715443 | Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+â¿¿and FOXP3+â¿¿immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. | Breast Cancer Research and Treatment | 2020 |
| 32426848 | Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. | Cancer | 2020 |
| 32259783 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 31869450 | The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. | Cancer | 2020 |
| 32468955 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. | J Clin Oncol | 2020 |
| 31806448 | Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer. | Clinical Breast Cancer | 2020 |
| 33843847 | Neratinib in the early-stage/extended adjuvant breast cancer patient: Q&A. | Clinical Advances in Hematology and Oncology | 2020 |
| 33843845 | Neratinib in early-stage breast cancer: clinical trial data. | Clinical Advances in Hematology and Oncology | 2020 |
| 33843839 | Treatment goals in the management of HER2-positive metastatic breast cancer. | Clinical Advances in Hematology and Oncology | 2020 |
| 33843842 | Neratinib: an option for HER2-positive metastatic breast cancer--Q&A. | Clinical Advances in Hematology and Oncology | 2020 |
| 33843843 | Neratinib in the early-stage/extended adjuvant breast cancer patient. | Clinical Advances in Hematology and Oncology | 2020 |
| 33843838 | Neratinib: an option for HER2-positive metastatic breast cancer. | Clinical Advances in Hematology and Oncology | 2020 |
| 32710663 | Progress in breast cancer research amid the COVID-19 gloom. | Cancer | 2020 |
| 32696319 | Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. | Breast Cancer Research and Treatment | 2020 |
| 32803324 | Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer. | Current Treatment Options in Oncology | 2020 |
| 32620961 | Implementation of a chemotherapy stewardship process. | American Journal of Health-System Pharmacy | 2020 |
| 31206611 | Race, breast cancer, and prognosis: Where biology is queen? | Cancer | 2019 |
| 31861131 | Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling. | Cancers | 2019 |
| 30387877 | Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer? | Cancer | 2019 |
| 30563890 | The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer. | Cancer Research | 2019 |
| 30745109 | Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. | Clinical Breast Cancer | 2019 |
| 30846407 | ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER/HER2 Breast Cancer. | Clinical Breast Cancer | 2019 |
| 30787125 | NCCN Guidelines Insights: Breast Cancer, Version 3.2018. | J Natl Compr Canc Netw | 2019 |
| 29107218 | Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer. | Biomaterials | 2018 |